IP Library Granted Patent US 9,993,437
Granted Patent B2
US 9,993,437 · App. 12/746,375 · Granted Jun 12, 2018

Mesoporous silica nanoparticles for biomedical applications

Inventors: Monty Liong (Los Angeles, CA); Jie Lu (Los Angeles, CA); Fuyuhiko Tamanoi (Los Angeles, CA); Jeffrey I. Zink (Sherman Oaks, CA); Andre Nel (Los Angeles, CA)
Assignee: The Regents of the University of California
A61K9/5115A61K9/5094A61K31/337A61K31/4375A61K49/0002A61K49/0043A61K49/0052A61K49/0093A61K49/183B82Y5/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,993,437
App. No.
12/746,375
Granted
Jun 12, 2018
Kind
B2
Abstract

A submicron structure includes a silica body defining a plurality of pores that are suitable to receive molecules therein, the silica body further defining an outer surface between pore openings of the plurality of pores; and a plurality of anionic molecules attached to the outer surface of the silica body. The anionic molecules provide hydrophilicity to the submicron structure and are suitable to provide repulsion between other similar submicron structures, and the submicron structure has a maximum dimension less than one micron.

Claims (29)

1. A submicron structure for delivering anticancer drugs into cancer cells, comprising:

a silica body defining a plurality of pores, where said plurality of pores are suitable to receive anticancer molecules therein and to subsequently release said anticancer molecules therefrom, said silica body further defining an outer surface between pore openings of said plurality of pores; and

a plurality of anionic molecules attached only to said outer surface of said silica body such that said plurality of pores are free of said plurality of anionic molecules thereby permitting said plurality of pores to receive anticancer molecules therein and to subsequently release said anticancer molecules therefrom;

wherein said anionic molecules provide hydrophilicity to said submicron structure and are suitable to provide repulsion between other similar submicron structures; and

wherein said submicron structure has a maximum dimension less than one micron.

2. A submicron structure according to claim 1 , wherein said plurality of anionic molecules comprise a phosphonate moiety.

3. A submicron structure according to claim 1 , wherein said plurality of anionic molecules are trihydroxysilylpropyl methylphosphonate.

4. A submicron structure according to claim 1 , further comprising a nanoparticle of magnetic material formed within said silica body of said submicron structure.

5. A submicron structure according to claim 4 , wherein said nanoparticle of magnetic material is an iron oxide nanoparticle.

6. A submicron structure according to claim 4 , wherein said nanoparticle of magnetic material has a maximum dimension greater than about 5 nm and less than about 30 nm.

7. A submicron structure according to claim 1 , further comprising a nanoparticle of gold formed within said silica body of said submicron structure.

8. A submicron structure according to claim 1 , further comprising a plurality of folate ligands attached to said outer surface of said silica body of said submicron structure.

9. A submicron structure according to claim 1 , further comprising a fluorescent molecule attached to said silica body of said submicron structure.

10. A submicron structure according to claim 9 , wherein said fluorescent molecule attached to said silica body is an amine-reactive fluorescent dye attached by being conjugated with an amine-functionalized silane.

11. A submicron structure according to claim 10 , wherein said fluorescent molecule is selected from the group consisting of fluorescein isothiocyanate, N-hydroxysuccinimide fluorescein (NHS-fluorescein), rhodamine B isothiocyanate, tetramethylrhodamine B isothiocyanate, and Cy5.5 NHS ester.

12. A composition for delivering anticancer drugs into cancer cells, said composition comprising a plurality of mesoporous silica nanoparticles, wherein each mesoporous silica nanoparticle of said plurality of mesoporous silica nanoparticles comprises:

a silica body defining a plurality of pores, where said plurality of pores are suitable to receive anticancer molecules therein and to subsequently release said anticancer molecules therefrom, said silica body further defining an outer surface between pore openings of said plurality of pores; and

a plurality of anionic molecules attached only to said outer surface of said silica body such that said plurality of pores are free of said plurality of anionic molecules such that said plurality of pores remain suitable to receive anticancer molecules therein and to subsequently release said anticancer molecules therefrom.

13. A composition according to claim 12 , wherein said plurality of anionic molecules comprise a phosphonate moiety.

14. A composition according to claim 12 , wherein said plurality of anionic molecules comprise trihydroxysilylpropyl methylphosphonate.

15. A composition according to claim 12 , wherein each of said plurality of mesoporous silica nanoparticle comprises a core comprising a magnetic material.

16. A composition according to claim 12 , wherein each of said plurality of mesoporous silica nanoparticle comprises a core comprising a material that is optically dense to x-rays.

17. A composition according to claim 12 , wherein each of said plurality of mesoporous silica nanoparticle comprises a plurality of folate ligands attached thereto.

18. A composition according to claim 12 , wherein said plurality of mesoporous silica nanoparticles has an ensemble average maximum dimension less than about 300 nm.

19. A composition according to claim 12 , wherein said plurality of mesoporous silica nanoparticles has an ensemble average maximum dimension greater than about 50 nm and less than about 150 nm.

20. A submicron structure according to claim 1 , wherein said plurality of pores contain hydrophobic anticancer molecules therein.

21. A composition according to claim 12 , wherein said plurality of pores contain hydrophobic anticancer molecules therein.

22. A submicron structure according to claim 1 , wherein said plurality of pores contain a drug selected from the group consisting of camptothecin, paclitaxel, resveratrol, etoposide, and carmustine.

23. A composition according to claim 12 , wherein said plurality of pores contain a drug selected from the group consisting of camptothecin, paclitaxel, resveratrol, etoposide, and carmustine.

Assignments (1)
CONFIRMATORY LICENSE Recorded Jul 23, 2010
From: UNIVERSITY OF CALIFORNIA LOS ANGELES
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 024732/0702 →
Continuity (2)
Provisional Application 60996827 · Dec 6, 2007
Related Publication 20100255103A1 · Oct 7, 2010